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Abstract
Epigenetic modifications are important early events during carcinogenesis. In particular, hypermethylation of CpG islands in
the promoter region of tumor suppressor genes is a well-known mechanism of gene silencing that contributes to cancer
development and progression. Tissue factor pathway inhibitor 2 (TFPI-2) is a tumor suppressor involved in invasiveness
inhibition. Although TFPI-2 transcriptional silencing, through promoter hypermethylation, has been widely reported in
several human malignancies, it has never been explored in lymphoma. In the present study TFPI-2 methylation and gene
expression have been investigated in canine Diffuse Large B-cell lymphomas (cDLBCL). The methylation level of 23 CpGs
located within the TFPI-2 promoter was investigated by bisulfite-specific PCR and next generation amplicon deep
sequencing (GS Junior 454, Roche) in 22 cDLBCLs and 9 controls. For the same specimens, TFPI-2 gene expression was
assessed by means of Real-time RT-PCR. Sequence analysis clearly demonstrated that TFPI2 is frequently hypermethylated in
cDLBCL. Hypermethylation of the TFPI-2 promoter was found in 77% of DLBCLs (17 out of 22) and in one normal lymph
node. Globally, dogs with DLBCL showed a mean methylation level significantly increased compared to controls (p,0.01)
and analysis of hypermethylation by site identified 19 loci out of 23 (82%) with mean methylation levels from 2- to 120-fold
higher in cDLBCL. Gene expression analysis confirmed a significant down-regulation of TFPI-2 (p,0.05) in DLBCLs compared
with normal lymph nodes, suggesting that TFPI-2 hypermethylation negatively regulates its transcription. In addition, a
significant positive correlation (p,0.01) was found between TFPI-2 methylation levels and age providing the first indication
of age-associated epigenetic modifications in canine DLBCL. To conclude, our findings demonstrated that epigenetic
dysregulation of TFPI-2, leading to its reduced expression, is frequently detected in canine DLBCL. In the next future, the
aberrant TFPI-2 promoter hypermethylation may be considered in association with prognosis and therapy.
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Introduction
Canine diffuse large B-cell lymphoma (DLBCL) is an aggressive
malignancy of the mature B-lymphocytes showing significant
overlaps with the human disease and it is considered curable in less
than 10% of dogs. Although advances in treatment have improved
outcome, survival time is quite variable, ranging from months to
years [1]. This incomplete success indicates the need for further
studies to elucidate the pathogenesis through the identification of
altered gene expression and cellular pathways, thereby influencing
the aggressive behavior of DLBCL, and representing a target for
novel therapeutic strategies.
In human DLBCL, gene-expression profiling has identified two
biologically and clinically distinct molecular subtypes, which
consistently correlate with treatment response, regardless of the
regimen used ([2] for a review). Nevertheless, paucity remains in
the understanding of the molecular events underlying the
development and progression of DLBCL, especially in terms of
activation of oncogenes or inactivation of tumor suppressor genes
(TSG). Recently, it has become clear that, in addition to genetic
changes (i.e. mutations, rearrangements), epigenetic modifications
represent an important step in the pathogenesis of lymphoma, and
such changes may be of interest in the definition of prognosis and
delineation of specific therapy [3]. A common epigenetic event is
DNA methylation at cytosine residues of CpG islands [4]. CpG
islands are short CpG-rich regions, often mapping at the promoter
and exonic regions of the gene. Increased methylation of CpG
islands within gene promoters is associated with transcriptional
gene silencing. In particular, hypermethylation of CpG islands in
the promoter region of TSGs is a well-known mechanism of gene
silencing that contributes to cancer development and progression
[5]. Identifying aberrant methylated genes may provide better
understanding of the pathogenesis of lymphoma, thereby paving
the way for the development of novel tumor markers and
therapeutic targets.
A candidate gene for epigenetic regulation of lymphomagenesis
is Tissue Factor Pathway Inhibitor-2 (TFPI-2), a Kunitz-type
serine proteinase inhibitor that directly regulates the activation of
matrix metallo-proteinases (MMPs) and plays a significant role in
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the regulation of ECM degradation, which is an essential step for
cell remodeling, as well as tumor invasiveness and metastasis. In
humans, TFPI-2 is inactivated or absent during tumor progres-
sion, conferring an important role for this gene in the pathogenesis
of malignancies [6]. Aberrant methylation has been suggested as a
possible mechanism for loss of TFPI-2 expression in several
human cancers [7–11].
We recently characterized the transcriptome profiles of twenty-
one dogs with DLBCL and five normal lymph nodes by using an
array–based approach [12]. Statistical analyses identified two
molecular subtypes similarly to human DLBCL. These two
clusters revealed distinct signatures with NFKB2 and other genes
related to proliferation having increased expression in the main
subgroup. Two probe sets revealed a significant down-regulation
of TFPI-2 mRNA levels in both DLBCL groups compared to
healthy controls.
The role of TFPI-2 in hematopoietic malignancies is scarcely
documented. Epigenetic dysregulation of TFPI-2, leading to its
reduced expression, has been observed in pediatric acute myeloid
leukemia [13], while no information is available for lymphoma.
Major improvements in sequencing technologies have now
provided an unprecedented opportunity to examine the cancer-
associated genomic alterations even in non-model species.
The aim of the present study was to investigate the TFPI-2
epigenetic status in lymph nodes from dogs with DLBCL and
healthy controls. TFPI-2 methylation levels were quantified by
means of bisulfite-specific PCR and next generation amplicon
deep sequencing. Additionally, the methylation status of TFPI-2
promoter has been correlated to gene expression levels in order to
evaluate whether abnormal methylation of the promoter region
might be responsible for TFPI-2 transcription silencing.
Materials and Methods
Samples and Nucleic Acid Extraction
All lymphoma samples were taken as part of normal diagnostic
procedures from dogs with newly diagnosed, previously untreated
lymphoma. Only dogs with confirmed DLBCL after histopatho-
logical and immunohistochemical analysis (CD20/CD79 marker
analysis) were enrolled (Table 1). The study was approved by the
Table 1. Samples included in the study.
ID Breed Age Gender Stage Substage
Healthy ctrls Ctrl1 German shepherd 5 M
Ctrl2 Cane Corso 5 F
Ctrl3 Mixed breed 6 M
Ctrl4 Mixed breed 4 M
Ctrl5 Siberian husky 9 F
Ctrl6 Mixed breed 10 F
Ctrl7 Mixed breed 9 F
Ctrl8 American Pittbul 7 M
Ctrl9 Mixed breed 2 F
DLBCL DLBCL1 Mixed breed 14 F 5 a
DLBCL2 Scottish terrier 10 F 4 a
DLBCL3 Pyrenean sheepdog 12 M 3 a
DLBCL4 English setter 12 F 3 a
DLBCL5 Labrabor retriever 5 M 4 a
DLBCL6 Labrador retriever 6 F 4 a
DLBCL7 Mixed breed 7 F 3 a
DLBCL8 German shepherd 8 M 3 a
DLBCL9 Tibetian terrier 8 F 4 a
DLBCL10 Mixed breed 3 F 3 a
DLBCL11 Mixed breed 9 M 4 a
DLBCL12 Epagneul Breton 7 F 5 b
DLBCL13 Yorkshire terrier 6 M 5 b
DLBCL14 Mixed breed 12 F 5 a
DLBCL15 Cocker spaniel 5 F 3 a
DLBCL16 Mixed breed 4 F 3 a
DLBCL17 Mixed breed 6 F 4 a
DLBCL18 German shepherd 8 F 3 a
DLBCL19 Mixed breed 8 M 5 a
DLBCL20 Mixed breed 5 F 4 a
DLBCL21 Mixed breed 5 M 4 a
DLBCL22 Mixed breed 11 F 5 b
doi:10.1371/journal.pone.0092707.t001
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University Committee (protocol 20085MSFH2) and a mandatory
written consent from patient owners was also requested. Portion of
the tumour was obtained under sterile conditions. Normal lymph
node samples were obtained from healthy dogs.
Samples were preserved in RNA-later and stored at minus 80uC
prior to RNA and DNA extraction. For all samples, DNA
extraction was conducted using the DNeasy Blood & Tissue Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
specifications. Total RNA was extracted using the RNAeasy Mini
Kit (Qiagen) according to manufacturer’s specifications. For each
sample, RNA integrity and quality were estimated on the Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). DNA
and RNA concentrations were determined with a NanoDrop ND-
1000 UV-Vis spectrophotometer (NanoDrop Technologies, Wil-
mington, USA).
In silico Prediction of TFPI-2 CpG Island and Primer
Design
In order to identify putative CpG island on promoter region,
TFPI-2 genomic sequence (ENSCAFG00000002040), as stored on
Ensembl genome browser (http://www.ensembl.org/index.html),
including 1000 bp upstream the ATG site was employed as query
sequence. Two different softwares, CpGPlot software (http://
www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/) and MethylPri-
mer Express v1.0 (Applied Biosystem) were applied. Parameters set
for CpG island identification were: 1) minimun length of 200 nt, 2)
CG content $50% and, 3) CpG observed/CpG expected ratio $
0.6.
On the CpG island identified, Bisulfite-specific primers (BSPs)
were then designed by means of Methyl Primer Express software
to amplify a region of 493 bp (see Table 2). In the same way, a
second primer pair was designed as ‘‘template specific portion’’ of
Fusion primers (see below) employed for 454 amplicon library
preparation (see Table 2).
Bisulfite Treatment and PCR Amplification
For each sample, a total of 400 ng of genomic DNA was
bisulfite treated using the MethylCode Bisulfite Conversion Kit
(Invitrogen, Carlsbad, California) following manufacturer’s spec-
ifications. A total of 10 ng of bisulfite-converted DNA was then
employed as template for first-round PCR using TFPI2_2F and
Table 2. Primer pairs employed for PCR amplification and amplicon library preparation.
Primer Primer sequence Amplicon (bp)
First-round PCR TFPI2_2F GGGGAGGTAGGTTTAATTTGG 493
TFPI2_Rd TCCTAAACRCCCTATACAACTAAAA
Amplicon library preparation TFPI2_LF GTGTGGGGTATGAATTAGTTAGG 212
TFPI2_LR AACCAACRAAATCCATAC
doi:10.1371/journal.pone.0092707.t002
Figure 1. Schematic representation of of the TFPI-2 gene and CpG island. The black boxes indicate exons, +1 indicates the translation start
site. Each vertical bar represents a CpG dinucleotide. From 2284 to +586 is the location of the CpG island, the grey box (from 2196 to +16) indicates
the region analyzed by Bis-seq.
doi:10.1371/journal.pone.0092707.g001
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TFPI2_Rd primers (see Table 2) in order to amplify a portion of
493 bp of TFPI-2 promoter. Cycling conditions were: initial
incubation at 94uC for 2 min followed by 35 cycles at 94uC for
20 s, 61.7uC for 30 s and 72uC for 1 min. A final extension step at
72uC for 5 min was added at the end of the last cycle.
Amplification products for each sample were then employed as
template for amplicon library preparation.
Amplicon Library Preparation and GS Junior 454
Sequencing
The amplicon library was purified using Agencourt AMPure
XP beads (Beckman Coulter, Krefeld, Germany), quantified using
the Quant-iT PicoGreen dsDNA kit (Invitrogen, Carlsbad, CA,
USA) and equimolar pooled together for the emPCR (library at
16107 molecules/ul). All data were generated using GS Junior
Sequencer Instrument software version 2.7 (Roche Applied
Science, Mannheim, Germany). Image processing and amplicon
pipeline analysis was performed using default settings of the GS
RunBrowser software version 2.7 (Roche Applied Science).
Gene Expression Analysis of TFPI-2
TFPI-2 expression levels were tested on 25 samples (7 healthy
controls and 18 DLBCLs) by means of real-time RT-PCR. A total
of 100 ng of RNA for each sample was reverse transcribed to
cDNA using High Capacity cDNA Reverse Transcription Kit
(Life Technologies). An aliquot (2.5 ml) of diluted (1:50) cDNA
template was amplified in a final volume of 10 ml, containing 5 ml
Platinum SYBR Green qPCR SuperMix-UDG 26 (Invitrogen)
and 0.25 ml of each gene-specific primer (10 mM). The amplifica-
tion protocol consisted of an initial step of 2 min at 50uC and
2 min at 95u followed by 45 cycles of 10 s at 95uC and 30 s at
60uC. All experiments were carried out in a LightCycler 480
thermocycler (Roche Diagnostics).
Each measurement was made in triplicate, and normalized to
the reference gene, transmembrane BAX inhibitor motif contain-
ing 4 (TMBIM4), which was also measured in triplicate. TMBIM4
Table 3. TFPI-2 mean methylation level and total number of reads for each sample. Gene expression levels measured by means of
qPCR are also reported.
Sample qPCR Reads Methylation level Mean methylation
Healthy ctrls Ctrl1 11.990 490 0.093 0.141 (60.08)
Ctrl2 1.336 459 0.135
Ctrl3 na 337 0.121
Ctrl4 na 273 0.033
Ctrl5 0.862 469 0.308
Ctrl6 1.290 349 0.076
Ctrl7 0.711 480 0.158
Ctrl8 1.563 427 0.216
Ctrl9 2.703 384 0.128
DLBCLs DLBCL1 0.030 410 0.671 0.448 (60.26)
DLBCL2 1.563 337 0.931
DLBCL3 4.636 364 0.692
DLBCL4 na 385 0.863
DLBCL5 0.184 485 0.007
DLBCL6 0.055 435 0.133
DLBCL7 0.031 441 0.481
DLBCL8 0.052 489 0.395
DLBCL9 1.441 331 0.361
DLBCL10 0.666 461 0.082
DLBCL11 1.324 236 0.696
DLBCL12 0.01 534 0.552
DLBCL13 0.000 402 0.147
DLBCL14 1.200 338 0.889
DLBCL15 0.114 352 0.129
DLBCL16 0.140 453 0.324
DLBCL17 na 374 0.414
DLBCL18 na 393 0.382
DLBCL19 2.264 457 0.549
DLBCL20 na 869 0.306
DLBCL21 1.546 397 0.526
DLBCL22 0.859 372 0.316
doi:10.1371/journal.pone.0092707.t003
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was chosen as reference in qRT-PCR assays since it was already
tested in canine lymphomas by Arico` et al. [14] and did not show
differences in its expression profile between healthy and pathologic
samples.
To evaluate the efficiency of each assay (TFPI-2 and TMBIM4),
standard curves were constructed amplifying two-fold serial
dilutions (from 1:20 up to 1:640) of the same cDNA, which was
used as calibrator. For both transcripts, efficiency of primer pairs
was within the range 95 - 105%. For each sample, the Cp
(Crossing point) was used to determine the relative amount of
target gene.
Data Analysis
The sets of reads from each sample, together with a ‘‘reference’’
genomic (not bisulfite converted) sequence, were analyzed by BiQ
Analyzer HT software [15]. The methylation status of each read
Figure 2. Bisulfite sequencing of the TFPI-2 CpG island. Each box indicates a CpG dinucleotide and each line of boxes represents analysis of a
single dog. Color gradation indicated the methylation level of each CpG site (0–1); 0, totally unmethylated; 1 totally methylated.
doi:10.1371/journal.pone.0092707.g002
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sequence was then determined based on a C to T conversion at
each CpG. For each analyzed sample-reference combination, the
software provides information about the methylation pattern per
read and the mean methylation level calculated for the amplicon.
In addition, a Pearl-Necklace diagram summarizes methylation
information for the whole set of filtered reads, by CpG loci. For
each site, distribution of the ‘‘methylated’’, ‘‘unmethylated’’ and
‘‘unrecognized’’ states in the given set of bisulfite reads is also
provided by the software.
The percentage of methylation (methylation level) at each CpG
site within each amplicon was calculated based on the number of
sequences containing methylated CpG sites versus the total
number of sequences analyzed, assigned values range between 0
(0%, site unmethylated) and 1 (100%, site totally methylated).
Statistical analyses were performed using a commercially
available statistical software program (SPSS v20.0). Data were
analysed using non-parametric statistical methods because of the
limited number of cases. Sample mean methylation levels, as well
as methylation percentage of individual CpG sites, were evaluated
for significant differences between healthy dogs and dogs with
DLBCL using the Kolmogorov-Smirnov test.
Mann-Whitney test was performed on qPCR data to test for
significant difference in TFPI-2 expression levels between controls
and DLBCLs. Spearman’s rank test was used to estimate the
correlation between mean methylation levels and TFPI-2 gene
expression values measured for the same individuals. A p-value ,
0.05 was selected as the level of significance.
Results
Twenty-two dogs with DLBCL were enrolled (Table 1). These
were 15 females and 7 males, and the median age was 7,5 years
(range, 3 to 14 years). Regarding breed, there were 11 mixed-
breed, 2 German shepherds, 2 Labrador retrievers, and one each
of Scottish terrier, Tibetian terrier, Pyrenean Sheepdog, Epagneul
Breton, Yorkshire terrier, Cocker spaniel and English setter.
Nine healthy dogs were enrolled (Table 1): 5 mixed-breeds, 1
Siberian husky, 1 American Pit Bull terrier, 1 German shepherd,
and 1 Cane Corso. Median age was 6 years (range, 2 to 10 years).
There were 5 females and 4 males.
TFPI-2 Amplicon Sequencing
A region encompassing 870 nucleotides (2284 to +586) and
containing 87 CG dinucleotides was identified as CpG island by
means of CpG Plot software (Figure 1). A fragment of 212 nt,
encompassing 23 CpG sites, was then chosen for ultradeep
bisulfite sequencing analysis (see Methods).
A total of 14,755 sequences was obtained in a single 454
sequencing run with average read length of 229.97 bp. After
quality filtering a total of 14,508 sequences (98.3%) was used for
computing the mean methylation level for each sample. On
average, 418 sequence reads (range of reads 236–869, including
both forward and reverse strands) were obtained for each dog (see
Table 3).
Table 4. Kolmogorov-Smirnov test on 23 individuals TFPI-2 promoter CpG sites.
Site p-value DLBCL n22 p-value DLBCL n17(a)
CpG1 0.082 0.014*
CpG2 0.517 0.410
CpG3 0.438 0.137
CpG4 0.143 0.034*
CpG5 0.016* 0.005**
CpG6 0.537 0.224
CpG7 0.17 0.058
CpG8 0.18 0.068
CpG9 0.143 0.034*
CpG10 0.138 0.031*
CpG11 0.622 0.239
CpG12 0.045* 0.006**
CpG13 0.537 0.410
CpG14 0.106 0.013*
CpG15 0.35 0.063
CpG16 0.143 0.031*
CpG17 0.016* 0.001**
CpG18 0.011* 0.002**
CpG19 0.042* 0.012*
CpG20 0.011* 0.002**
CpG21 0.007** 0.002**
CpG22 0.235 0.068
CpG23 0.031* 0.013*
(a)DLBCL5, DLBCL6, DLBCL10, DLBCL13 and DLBCL15 excluded from the analysis.
*p,0.05, **p,0.01.
doi:10.1371/journal.pone.0092707.t004
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Quantitative DNA Methylation Analysis
For each sample, the mean methylation level (see Table 3) and
the percentage of methylation for each CpG locus (reported in File
S1) were calculated by means of BiQ Analyzer HT. Seventeen out
of 22 DLBCLs (77.3%) exhibited a mean methylation$0.3, with 9
samples (40.9%) with level of methylation greater than 0.5.
Control lymph nodes showed a mean methylation #0.3. Only one
sample had a mean methylation of 0.31. Kolmogorov-Smirnov
test was performed in order to compare methylation levels
between controls and DLBCLs. A significant 3.2-fold increase of
mean methylation levels in DLBCL dogs was observed compared
to control lymph nodes (p,0.01). Five DLBCLs (i.e. DLBCL5,
DLBCL6, DLBCL10, DLBCL13 and DLBCL15) did not show
hypermethylation in TFPI-2 promoter, with mean methylation
levels significantly reduced (p,0.01) compared to all other
DLBCL samples.
DNA Methylation Patterns on Individual CpG Sites
When considering each CpG site individually (Figure 2), only
one locus out of 23 showed a mean methylation percentage higher
than 50% in healthy controls compared with 7 loci (30.4%) found
in DLBCL samples (see File S1). The difference between the two
groups was more evident if the threshold of the mean methylation
percentage was lowered to 40% (0.4) with two loci (8.6%) and 15
loci (65.2%) for controls and DLBCL dogs, respectively. Statistical
analysis for each CpG site identified eight loci with significant
difference (p,0.05) in methylation level between DLBCL and
control group (see Table 4). Excluding DLBCL5, DLBCL6,
DLBCL10, DLBCL13 and DLBCL15 from the analysis, the
number of loci found differentially methylated between the two
groups increased up to 14 out of 23 (see Table 3).
Relationship between TFPI-2 Methylation Status and
Gene Expression Levels
For a subset of samples including 7 controls and 18 DLBCLs
(see Table 3), the association between TFPI-2 methylation levels
and gene expression values was assessed by means of real-time
RT-PCR (Figure 3). Gene expression analysis identified a
significant down-regulation of TFPI-2 in DLBCL (p,0.05), with
normal lymph nodes having 3-fold increased expression levels.
Pearson correlation analysis between TFPI-2 methylation levels
and gene expression, however, revealed a rho coefficient = 0.05
indicating that there is no linear correlation between the two
variables (Figure 3).
Expression values obtained with qPCR were also correlated
with those previously obtained using Canine genome 2.0 array
(Affymetrix) [12] for the same specimens (n 19). Comparative
analysis of microarray and qPCR expression data are reported in
File S2. Statistical analysis identified a positive and highly
significant correlation between qPCR and two microarray probes
(Spearman’s 0.68# rho #0.78, p,0.01), thus validating micro-
array results.
The two oligonucleotide probes, Cfa.13994.1.S1_at and
CfaAffx.3983.1.S1_at, showed a significant down-regulation of
TFPI-2 in DLBCLs compared to control lymph nodes (p,0.05).
However, as for qPCR, no linear correlation was documented
between mean methylation levels and gene expression values.
Relationship between TFPI-2 Methylation Status and
Clinical Data
The Spearman’s correlations between TFPI-2 methylation
levels, age, clinical signs, stage and substage were also assessed
for all samples. Statistical analysis identified a significant positive
Figure 3. Relationship between TFPI-2 methylation and gene expression levels. A. Boxplot of TFPI-2 methylation levels measured in DLBCL
and Healthy control group. B. Boxplot of TFPI-2 gene expression levels measured in the same samples and C. Correlation between TFPI-2
methylation and its gene expression values.
doi:10.1371/journal.pone.0092707.g003
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correlation (Spearman’s rho 0.745, p,0.01) between methylation
levels and age of DLBCL dogs. The number of dogs older than 8
years in healthy control group was too low for properly assessing
the correlation age/methylation in this group.
No correlation was observed between TFPI-2 methylation levels
and staging of the disease (data not shown). The same analysis was
conducted considering TFPI-2 mRNA levels and no correlation
was found between TFPI-2 expression and age or staging.
Discussion
DLBCL is the most common subtype of canine lymphoma
[14,16] and it shares many features with the human counterpart,
including clinical presentation, biological behavior, tumor genetics
and treatment response [1]. A genome-wide hypomethylation
associated with a simultaneous promoter-associated CpG island
hypermethylation is now considered a hallmark of cancer [17].
Recently, genome-scale studies reported that aberrant DNA
methylation occurs at specific genomic locations [18,19]. It is
widely reported that TSGs are frequently hypermethylated in
neoplastic cells. This epigenetic modification contributes to the
suppression of their expression ([20] and references therein) and
makes cancer cells acquire growth advantages. However, the role
of the single gene aberrant DNA methylation in controlling gene
expression and tumor progression is still under debate.
TFPI-2 has been recently proposed as TSG since it plays a
significant role in the maintenance of the stability of the tumor
microenvironment and in the prevention of cancer progression by
inhibiting tumor-related angiogenesis and members of ECM.
In particular, TFPI-2 has been reported to inhibit MMP-1,
MMP-2, MMP3 and MMP-9 [21–23], proteolytic ECM enzymes
whose increased expression has been demonstrated to be strongly
associated with prognosis in canine lymphoma [14,24].
The transcriptional silencing of TFPI-2 by hypermethylation in
the promoter region has been recently demonstrated in many
human cancers, including nasopharyngeal, colorectal and gastric
carcinoma [9–11,25]. No studies report TFPI-2 methylation in
human lymphoma, although this phenomenon is described in
pediatric acute myeloid leukemia [13].
In the present study, bisulfite conversion and 454 amplicon
sequencing (Bis-seq) provided an accurate quantification of TFPI-
2 methylation levels with a single base resolution, allowing the
identification of CpG sites aberrantly methylated in canine
DLBCLs. Sequence analysis clearly demonstrated that TFPI2 is
frequently hypermethylated in canine DLBCL. Globally, dogs
with DLBCL showed a mean methylation level over three-fold
higher than controls and hypermethylation of the TFPI-2
promoter was found in 77% of DLBCLs (17 out of 22) against
only one normal lymph node (,11%). The analysis of hyper-
methylation by site identified 19 loci out of 23 (82%) with mean
methylation levels from 2- to 120-fold increased in DLBCL (File
S1) and 8 CpG loci were significantly (p,0.05) hypermethylated
in DLBCL dogs compared to controls.
One of the proposed regulatory mechanisms ascribed to DNA
methylation is to prevent the binding of transcription factors [26].
In dogs, TFPI-2 gene is located in chromosome 14 and, similarly
to humans, in silico analysis of its promoter region identified the
binding sites for several transcription factors, including SP1,
activating enhancer-binding protein-1 (AP-1), nuclear factor kappa
B (NF-kB), lymphoid transcription factor-1 (Lyf-1) and Myeloid
zinc finger 1 (MZF-1).
Here, bisulfite sequencing results provided a partial represen-
tation of the potential control apparatus of TFPI-2. However, the
region analyzed in the present study included both AP-1 and NF-
kB putative binding sites. No CpG dinucleotides were located in
close proximity to the AP-1 consensus sequence, while the region
with the highest density of hypermethylated CpG sites (Sites 17–
21, see Table 4) encompassed the NF-kB binding motif. It is well
known that the transcription factor NF-kB controls a wide range
of genes that are involved in multiple cellular processes, from
apoptosis to proliferation and inflammation. In particular, Rel/
NF-kB families of transcription factors are key regulators of B-cell
development, proliferation and survival [27]. Human and canine
DLBCLs are characterized by constitutive canonical NF-kB
activity [28,29] that promotes lymphomagenesis and chemother-
apy resistance via overexpression of anti-apoptotic NF-kB target
genes (i.e. Cyclin D1 and D2, Bcl-2). Very recently Mudaliar and
co-workers [29], through the analysis of differentially expressed
probe sets in canine and human DLBCL, found molecular
signatures shared between dog and human. In particular, they
reported the enrichment of the NF-kB signalling pathway in both
species, with potential therapeutic implications, and further
underscoring the dog as a translation model for human DLBCL.
In humans, mutations at either AP-1 or SP1 sites resulted in
reduced TFPI-2 activity while NF-kB has not been demonstrated
to directly control TFPI-2 transcription [30]. Whether TFPI-2 in
dogs is controlled by the same mechanisms as in humans has not
been assessed yet. However, the location of NF-kB binding motif
in canine TFPI-2 promoter (i.e. immediately upstream of the ATG
site) is different from humans, and it is unknown whether NF-kB
exerts a role in regulating the transcription of this gene in dogs. In
this context, it cannot be excluded that the hypermethylation of
the NF-kB binding motif may exert a role in preventing the
binding of this transcription factor.
The second aim of the present study was to assess the
relationship between TFPI-2 methylation status and its gene
expression levels measured by means of qRT-PCR. TFPI-2
showed a significant down-regulation in DLBCL compared with
normal lymph nodes, suggesting that TFPI-2 hypermethylation
negatively regulates its transcription.
In comparison with previous ‘‘semi-quantitative’’ approaches
that mainly relied on the sequencing of 5–10 clones for measuring
gene methylation levels, NGS allowed for a proper quantification
of each CpG status. We decided then to verify whether a linear
correlation between methylation levels and gene expression values
could be determined.
No linear correlation was found between mean methylation
levels and gene expression values. This was not unexpected, since
a certain level of discordance between methylation and gene
expression has been reported in both humans and dogs [31,32]. In
these cases, gene promoters showed mixed methylation patterns
with regions completely methylated and regions unmethylated, the
latter being responsible for the continued gene expression.
In the present study, the extremely high GC content of TFPI-2
promoter, and the approach chosen for amplicon sequencing (i.e.
sequencing only one amplicon in favor of a greater number of
sequences), limited bisulfite evaluation to one forth (212/870 nt) of
the entire CpG island thus giving only partial information on the
methylation levels of the promoter. Although a good indication of
the relationship between TFPI-2 methylation and gene transcrip-
tion has been achieved, the analysis of the entire promoter region
is needed in order to properly investigate the correlation between
methylation level and gene expression, as well as to identify
potential critical, hypomethylated, regions that allow transcription
in spite of global promoter hypermethylation or vice versa.
In this context, of particular interest are five DLBCL cases
(DLBCL5, DLBCL6, DLBCL10, DLBCL13 and DLBCL15) that
showed TFPI-2 transcription silencing even if the promoter
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regions appeared to be unmethylated (Table 3). In addition to the
binding of transcription factors, other mechanisms, known to
regulate gene transcription at different levels (i.e. recruitment of
other members of the ‘‘transcription machinery’’, interplay of
enhancer molecules or small non-coding RNAs) may participate in
controlling TFPI-2 mRNA levels thus leading to its silencing in
DLBCL samples in spite of lower methylation levels.
Multiple changes such as decreased telomere length and altered
gene expression have been linked to cellular aging. Recently,
genomic hypomethylation and accumulation of CpG island
hypermethylation has been associated with increasing age in
humans [33]. Several genome-wide studies have revealed strong
links between age-associated epigenetic changes and disease ([17]
for a review). In particular, the hematopoietic stem cell decline in
aging individuals was described as being determined by age-
dependent changes in DNA methylation. To our knowledge, a
similar phenomenon of accumulated promoter hypermethylation
has not been demonstrated in dogs. In the present study, a
significant positive correlation (rho 0.74, p,0.01) was appreciated
between TFPI-2 methylation levels and age of DLBCL dogs.
This finding is in accordance with the study by Hannum and
colleagues [33] where, by using a newly developed aging model
based on whole genome DNA methylation, tumor tissue appears
to be 40% older than the matched normal tissue from the same
individual.
Although a higher number of samples both from normal dogs
and dogs with DLBCL are needed, this study provides the first
indication of age-associated epigenetic modifications in dogs.
To conclude, our results demonstrated that TFPI-2 promoter
hypermethylation occurs frequently in DLBCL. TFPI-2 is also
expressed at lower levels in neoplastic lymphoid cells compared to
normal lymphoid cells, thus demonstrating an association between
methylation and silencing of TFPI-2 expression.
Identifying aberrant methylated genes may provide a better
understanding of the pathogenesis of canine DLBCL. The present
analysis is far from showing a prognostic utility of TFPI-2 in cases
of DLBCL. Further analysis will consider a set of canine
lymphoma cell lines to test the efficacy of hypomethylating agents
and a larger number of cases to assess whether TFPI-2 promoter
hypermethylation may be considered in association with prognosis
and therapy. In this context, novel gene therapy tools, including
recombinant adenoviral-mediated TFPI-2 delivery, are currently
being developed to regulate tumor growth providing potential
novel therapeutic approaches for the treatment of DLBCL in dogs
[34].
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